Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV003177170 | SCV003856755 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-11-22 | criteria provided, single submitter | clinical testing | The c.1005_1010delTGAGCG pathogenic mutation (also known as p.E336_R337del) is located in coding exon 9 of the TP53 gene. This pathogenic mutation results from an in-frame TGAGCG deletion at nucleotide positions 1005 to 1010. This results in the in-frame deletion of the glutamic acid and arginine residues at codons 336-337. This alteration has been observed in at least one individual with a personal and/or family history meeting Chompret criteria (Ambry internal data). This amino acid region is not well conserved in available vertebrate species and the impacted region is critical for protein function (Ambry internal data). In addition, this alteration is predicted to be deleterious by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |